SueWallSt
Sue Wall Street digs into the scams, cover-ups, and corporate faceplants that Wall Street hopes you’ll ignore. From fraud and insider trading to the whistleblowers who called it out we break down how the powerful play the game and sometimes get burned. We’re not lawyers or accountants, so don’t take this as legal or financial advice. Go to ZLK.com for more on the case and follow us for the next corporate faceplant.
#153 $UPST AI Model Overdrive When Algorithms Cut Too Deep
This episode dives into Upstart Holdings $UPST and a high stakes securities case where AI lending promises collided with unexpected model behavior. Built for investors, traders, and fintech watchers, we explore artificial intelligence credit models, loan approvals, macro sensitivity, and revenue volatility. Expect deep dive analysis, financial storytelling, and insights into algorithmic risk, fintech growth, and stock reactions.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#152 $UHG From Value Review to Fire Sale The United Homes Collapse
This episode breaks down United Homes Group $UHG and a dramatic governance clash that turned a “maximize shareholder value” strategy into a steep discounted buyout. Built for investors, traders, and real estate market watchers, we explore board resignations, insider control risk, strategic review conflicts, and stock crashes. Expect deep dive analysis, financial storytelling, and insights into corporate governance and small cap volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#151 $STLA EV Ambitions to Billion Euro Reset The Stellantis Shock
This episode dives into Stellantis $STLA and a massive business reset that stunned investors after bold electrification promises. Built for investors, traders, and auto industry watchers, we break down EV strategy risks, restructuring charges, earnings pressure, and stock volatility. Expect deep dive analysis, financial storytelling, and insights into electric vehicle demand, global auto trends, and market reactions.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#150 $NUAI AI Dreams to Oil Field Reality The New Era Collapse
This episode unpacks New Era Energy and Digital $NUAI and a complex securities case where AI data center ambitions collided with alleged permitting gaps and oil and gas liabilities. Built for investors, traders, and energy tech watchers, we explore regulatory risk, asset retirement obligations, related party concerns, and stock crashes. Expect deep dive analysis, financial storytelling, and insights into AI infrastructure hype and disclosure risk.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#149 $MEDP Book to Bill Breakdown When Cancellations Come Back
This episode dives into Medpace Holdings $MEDP and a high stakes securities case where strong guidance and “well behaved” cancellations collided with a disappointing book to bill miss. Built for investors, traders, and biotech service watchers, we break down CRO trends, backlog risk, cancellations, and revenue visibility. Expect deep dive analysis, financial storytelling, and insights into clinical research stocks and volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#148 $BW Billion Dollar Deal or Broken Narrative The Babcock and Wilcox Case
This episode dives into Babcock and Wilcox $BW and a high stakes AI data center deal that sent the stock soaring before raising serious investor questions. Built for investors, traders, and energy and AI market watchers, we break down backlog growth, contract risk, related party concerns, and stock volatility. Expect deep dive analysis, financial storytelling, and insights into infrastructure plays and market hype.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#147 $VITL ERP Rollout Chaos From Smooth Switch to Supply Shock
This episode breaks down Vital Farms $VITL and a supply chain disruption story tied to ERP system rollout risks, operational delays, and investor fallout. Built for investors, traders, and consumer goods watchers, we explore inventory systems, shipment slowdowns, retail shelf space loss, and earnings misses. Expect deep dive analysis, financial storytelling, and insights into execution risk and stock volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#146 $PINS Ad Revenue Reality Check The Pinterest Pullback
This episode breaks down Pinterest $PINS and a high stakes securities case tied to ad revenue pressure, tariff impacts, and investor expectations. Built for investors, traders, and digital ad watchers, we explore retail advertiser pullbacks, platform monetization risk, restructuring signals, and stock volatility. Expect deep dive analysis, financial storytelling, and insights into social media stocks and macro trends.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#145 $SMCI AI Boom to Export Control Shock The Super Micro Story
This episode dives into Super Micro Computer $SMCI and a high stakes controversy where explosive AI server growth collided with alleged export control violations. Built for investors, traders, and tech market watchers, we break down AI infrastructure demand, data center growth, compliance risks, and stock crashes. Expect deep dive analysis, financial storytelling, and insights into semiconductors, AI hype, and regulatory exposure.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#143 $IBRX Breakthrough Hype to FDA Reality Check
This episode dives into ImmunityBio $IBRX and a biotech controversy where bold cancer cure claims collided with regulatory scrutiny. Built for investors, biotech traders, and market watchers, we break down FDA warning letters, drug approval limits, clinical hype, and stock drops. Expect deep dive analysis, biotech storytelling, and insights into regulatory risk, cancer therapies, and volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#142 $GOSS Trial Design Trap The PROSERA Collapse
This episode unpacks Gossamer Bio $GOSS and a biotech breakdown where trial design risks collided with investor expectations. Built for biotech investors, traders, and market watchers, we explore Phase three trials, placebo response impact, clinical data risk, and stock crashes. Expect deep dive analysis, biotech storytelling, and insights into FDA pathways, trial design flaws, and volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#141 $ALDX Clinical Promise to FDA Rejection The Reproxalap Fallout
This episode dives into Aldeyra Therapeutics $ALDX and a biotech story that flipped from clinical optimism to regulatory shock. Built for investors, biotech traders, and market watchers, we break down drug trials, FDA complete response letters, inconsistent data, and stock collapse risk. Expect deep dive analysis, biotech storytelling, and insights into clinical trials, FDA decisions, and volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#140 $PSIX Data Center Dream to Margin Meltdown
This episode breaks down Power Solutions International $PSIX and a shocking shift from booming data center demand to collapsing margins and investor fallout. Built for traders, investors, and market watchers, we explore earnings volatility, margin compression, production inefficiencies, and stock price crashes. Expect deep dive analysis, financial storytelling, and insights into growth stocks, data center hype, and risk.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#139 $LU Accounting Shock When Financials Get Restated
This episode dives into Lufax Holdings $LU and a major accounting controversy involving restated financials, auditor concerns, and internal control failures. Built for investors, traders, and financial analysts, we break down earnings restatements, disclosure risks, audit red flags, and stock price reactions. Expect deep dive analysis, financial storytelling, and real insights into market trust and volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#138 $HTGC Valuation Illusion Inside the Hercules Capital Controversy
This episode dives into Hercules Capital $HTGC and a high stakes securities case questioning underwriting discipline, portfolio valuation, and deal sourcing practices. Built for investors, traders, and finance professionals, we break down net asset value N A V, private credit risk, software exposure, and market reactions. Expect deep dive analysis, investigative storytelling, and insights into BDC investing and stock volatility.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#137 $GEMI Crypto Pivot Chaos From Exchange Growth to Strategy Shock
This episode unpacks Gemini Space Station $GEMI and a dramatic post IPO shift that stunned investors. Built for crypto traders, retail investors, and market watchers, we break down exchange growth narratives, prediction markets, layoffs, executive exits, and global pullbacks. Expect deep dive analysis, financial storytelling, and insights into IPO risk, crypto volatility, and stock market reactions.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#136 $COTY Beauty Boom to Bust The Earnings Shock Story
In this episode, we break down the rise and reality check behind Coty Inc $COTY, uncovering a high stakes securities case tied to beauty industry trends, earnings guidance, and investor expectations. Built for investors, traders, and market watchers, this deep dive explores fragrance sales, Consumer Beauty struggles, margin pressure, and stock volatility. Expect sharp analysis, financial storytelling, and real market insights.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#135 $CIGL From Sky High Hype to Crash Landing The Concorde Collapse
This episode breaks down the explosive rise and سقوط of Concorde International Group $CIGL, blending true crime style storytelling with deep dive financial analysis. Built for retail investors, traders, and anyone navigating stock market risk, we unpack alleged WhatsApp scams, social media manipulation, low float stocks, and pump and dump dynamics. Expect investigative commentary, market insights, and real investor impact.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#134 $ATRA From Breakthrough to Breakdown The Atara Biotech Story
Dive into a gripping finance and biotech podcast episode unpacking Atara Biotherapeutics and the fall from FDA optimism to a securities class action. Perfect for investors, traders, and finance enthusiasts, this episode blends deep dive analysis, storytelling, and market insight. We explore $ATRA stock, FDA setbacks, manufacturing risks, and investor impact.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#133 $IT Strong Guidance or Silent Slowdown Inside Gartner Miss
Dive into the Gartner $IT controversy as we break down a securities class action tied to contract value growth, consulting revenue weakness, and alleged misleading guidance. This episode is for investors, traders, and anyone following tech services, enterprise demand, and market risk. Expect deep dives, real case analysis, and insights into slowing sales cycles, missed expectations, and sharp stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#132 $GO Growth Push or Costly Correction Inside Grocery Outlet Drop
Dive into the Grocery Outlet $GO controversy as we break down a securities class action tied to rapid store expansion, restructuring risks, and alleged misleading growth claims. This episode is for investors, traders, and anyone following retail stocks, expansion strategies, and market volatility. Expect deep dives, real case analysis, and insights into store closures, impairment charges, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#131 $ALIT Dividend Confidence or Collapse Inside Alight Unraveling
Dive into the Alight $ALIT controversy as we break down a securities class action tied to execution failures, weak growth, and alleged misleading statements about margins and dividends. This episode is for investors, traders, and anyone following SaaS, HR tech, and market risk. Expect deep dives, real case analysis, and insights into leadership exits, guidance cuts, and stock crashes.
Visit ZLK.com for more info.
Add our WhatsApp Channel.
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#130 $TCOM Antitrust Risk or Missed Warning Inside Trip.com Drop
Dive into the Trip.com $TCOM controversy as we break down a securities class action tied to antitrust investigations, regulatory risk in China, and alleged misleading disclosures. This episode is for investors, traders, and anyone following tech platforms, global markets, and market volatility. Expect deep dives, real case analysis, and insights into regulatory scrutiny, risk disclosures, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#129 $SLNO Breakthrough Drug or Hidden Risk Inside Soleno Fallout
Dive into the Soleno Therapeutics $SLNO controversy as we break down a securities class action tied to drug safety, rare disease treatments, and alleged misleading statements around Vykat XR. This episode is for investors, traders, and anyone following biotech stocks, FDA approvals, and market risk. Expect deep dives, real case analysis, and insights into safety concerns, patient outcomes, and stock declines.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#128 $ODD Beauty Tech or Broken Ads Inside Oddity Tech Shock
Dive into the Oddity Tech $ODD controversy as we break down a securities class action tied to digital advertising, customer acquisition costs, and algorithm driven disruptions. This episode is for investors, traders, and anyone following ecommerce, tech stocks, and market risk. Expect deep dives, real case analysis, and insights into ad auction dynamics, rising costs, and sudden stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#127 $NKTR Trial Trouble When Clinical Confidence Cracks
Dive into the Nektar Therapeutics $NKTR controversy as we break down a securities class action tied to biotech trials, protocol violations, and alleged misleading statements around clinical execution. This episode is for investors, traders, and anyone following biotech stocks, drug development, and market risk. Expect deep dives, real case analysis, and insights into trial integrity, statistical outcomes, and stock reactions.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#126 $MNDY Growth Story or Slowing Momentum Inside monday.com Shift
Dive into the monday.com $MNDY controversy as we break down a securities class action tied to SaaS growth, enterprise sales trends, and shifting long term revenue targets. This episode is for investors, traders, and anyone following tech stocks, cloud platforms, and market volatility. Expect deep dives, real case analysis, and insights into slowing customer growth, longer sales cycles, and guidance cuts.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#125 $EOSE Battery Boom or Broken Ramp Inside Eos Energy Miss
Dive into the Eos Energy $EOSE controversy as we break down a securities class action tied to battery technology, manufacturing automation, and missed revenue guidance. This episode is for investors, traders, and anyone following energy storage, clean tech, and market risk. Expect deep dives, real case analysis, and insights into production delays, downtime issues, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#124 $DRVN Restatement Shock When Financials Can’t Be Trusted
Dive into the Driven Brands $DRVN controversy as we break down a securities class action tied to financial restatements, internal control failures, and accounting errors across multiple years. This episode is for investors, traders, and anyone following earnings quality, corporate governance, and market risk. Expect deep dives, real case analysis, and insights into unreliable financials, audit issues, and stock crashes.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#123 $CWH Inventory Control or Margin Collapse Inside Camping World
Dive into the Camping World $CWH controversy as we break down a securities class action tied to inventory management, margin pressure, and alleged misleading statements about financial discipline. This episode is for investors, traders, and anyone following retail stocks, RV market trends, and market risk. Expect deep dives, real case analysis, and insights into inventory missteps, declining margins, and dividend cuts.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#122 $CHOW Pump Hype or Engineered Collapse Inside ChowChow Cloud
Dive into the ChowChow Cloud $CHOW controversy as we break down a securities class action tied to IPO activity, alleged stock manipulation, and social media driven trading schemes. This episode is for investors, traders, and anyone following micro cap stocks, IPO risks, and market volatility. Expect deep dives, real case analysis, and insights into pump and dump patterns, low float risks, and sudden stock crashes.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#121 $BSX Heart Growth Hype or Hidden Slowdown Inside Boston Scientific
Dive into the Boston Scientific $BSX controversy as we break down a securities class action tied to medical devices, electrophysiology growth, and alleged misleading statements around FARAPULSE adoption. This episode is for investors, traders, and anyone following healthcare stocks, medtech innovation, and market risk. Expect deep dives, real case analysis, and insights into competition, slowing procedure volumes, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#120 $AQST FDA Delay Shock The Allergy Drug Setback Investors Missed
Dive into the Aquestive Therapeutics $AQST controversy as we break down a securities class action tied to biotech approvals, FDA delays, and alleged misleading timelines around Anaphylm. This episode is for investors, traders, and anyone following biotech stocks, drug approvals, and market volatility. Expect deep dives, real case analysis, and insights into regulatory risk, clinical setbacks, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#119 $APO Wall Street Secrets The Apollo Epstein Controversy
Dive into the Apollo Global Management $APO controversy as we break down a securities class action tied to alleged undisclosed ties, reputational risk, and investor disclosures. This episode is for investors, traders, and anyone following hedge funds, Wall Street news, and market transparency. Expect deep dives, real case analysis, and insights into corporate governance, disclosure risks, and stock reactions.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#118 $SNOW Cloud Growth or Hidden Headwinds Inside the Snowflake Drop
Dive into the Snowflake $SNOW controversy as we break down a securities class action tied to cloud computing, consumption based revenue, and unexpected growth headwinds. This episode is for investors, traders, and anyone following tech stocks, data platforms, and market volatility. Expect deep dives, real case analysis, and insights into pricing models, efficiency impacts, and stock drops.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#117 $NAVN IPO Turbulence What Investors Weren’t Told
Dive into the Navan $NAVN controversy as we break down a securities class action tied to IPO disclosures, rising sales and marketing costs, and post IPO stock declines. This episode is for investors, traders, and anyone following tech stocks, IPOs, and market risk. Expect deep dives, real case analysis, and insights into financial transparency, growth metrics, and investor expectations.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#116 $LAKE Growth Strategy or Cracks in the Foundation Inside Lakeland Fallout
Dive into the Lakeland Industries $LAKE controversy as we break down a securities class action tied to acquisitions, operational challenges, and missed financial guidance. This episode is for investors, traders, and anyone following industrial stocks, M and A strategies, and market risk. Expect deep dives, real case analysis, and insights into earnings misses, supply chain issues, and stock declines.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#115 $FBRT Dividend Cut Shock Income Investors Blindsided
Dive into the Franklin BSP Realty Trust $FBRT controversy as we break down a securities class action tied to REIT dividends, commercial real estate debt, and alleged misleading statements about earnings power. This episode is for income investors, traders, and anyone following dividend stocks, REITs, and market risk. Expect deep dives, case analysis, and insights into dividend cuts, earnings pressure, and investor expectations.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#114 $CORT FDA Shock The Approval That Never Came
Dive into the Corcept Therapeutics $CORT controversy as we break down a securities class action tied to biotech approvals, FDA setbacks, and alleged misleading statements حول relacorilant. This episode is for investors, traders, and anyone following biotech stocks, clinical trials, and market volatility. Expect deep dives, case analysis, and insights into FDA risk, insider selling, and stock crashes.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
#113 $ZYXI Shocking Growth or Alleged Fraud Inside Zynex Collapse
Dive into the Zynex $ZYXI controversy as we break down a massive securities class action tied to alleged overbilling, medical device supply practices, and inflated revenue growth. This episode is for investors, traders, and anyone following healthcare stocks, fraud allegations, and market risk. Expect deep dives, real case analysis, and insights into billing practices, regulatory scrutiny, and stock collapses.
Visit ZLK.com for more info.
Add our WhatsApp Channel
We’re not lawyers or accountants, so don’t take this as legal or financial advice.
